Published on 23 September 2015
Overview of non-innovator biological products in India
Author(s): GR Soni, PhD
biosimilar, CDSCO, Innovator Reference Biological Product, non-innovator biologic, RCGM
DOI: 10.5639/gabij.2020.0901.006
12.426 views
Published on 23 September 2015
Author(s): GR Soni, PhD
biosimilar, CDSCO, Innovator Reference Biological Product, non-innovator biologic, RCGM
DOI: 10.5639/gabij.2020.0901.006
12.426 views
Published on 12 June 2017
Author(s): Christoph Stoller, Emilia Minodora Voiculescu, PharmD, Professor Stephan Krähenbühl, MD, PhD
innovation, pharmacy regulation, value-added medicines
DOI: 10.5639/gabij.2017.0603.027
12.425 views
Published on 27 April 2016
Author(s): Alejandra Babini, Associate Professor Valderilio Feijó Azevedo, MD, PhD, MSc, Igor Age Kos, Pablo Matar, PhD, Professor Fabio V Teixeira, MSc, MD, PhD
biosimilarity, extrapolation, infliximab, interchangeability, monoclonal antibodies, rituximab
DOI: 10.5639/gabij.2016.0502.017
12.357 views
Published on 11 October 2012
Author(s): Carlo Petrini, PhD
bioethics, drugs, ethics committees, legislation, risk, safety
DOI: 10.5639/gabij.2012.0103-4.034
12.314 views
Published on 06 February 2015
Author(s): Professor Mohamed Izham Mohamed Ibrahim, PhD
generic medicines, pharmaceutical policy, Qatar
DOI: 10.5639/gabij.2015.0401.003
12.262 views
Published on 16 June 2014
Author(s): GaBI Journal Editor
biosimilar, clinical development, commercializaiton, INN
DOI: 10.5639/gabij.2014.0303.035
12.262 views
Published on 14 June 2018
Author(s): Michael S Reilly, Esq, Peter J Pitts, BA
Biological Qualifier (BQ), biosimilar, INN, medicines regulation, MENA (Middle East and North Africa)
DOI: 10.5639/gabij.2018.0703.021
12.103 views
Published on 03 July 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.015
12.100 views
Published on 12 March 2012
Author(s): Amanj Kurdi, BSc, PhD, Axel Leporowski, MD, Brian Godman, BSc, PhD, Holly McCabe, MSc, Marion Bennie, MSc, Professor Alec Morton, PhD, Sean MacBride-Stewart, MSc, Simon Hurding, MD
drug utilization, expenditure, generics, PPIs, reforms, Scottish NHS
DOI: 10.5639/gabij.2018.0704.030
12.094 views
Published on 26 March 2015
Author(s): Omotayo Fatokun, PhD, Professor Mohamed Azmi Hassali, PhD, Professor Mohamed Izham Mohamed Ibrahim, PhD
generic medicines, Malaysia, market entry, patent, pharmaceutical market
DOI: 10.5639/gabij.2016.0504.046
12.094 views
Published on 20 January 2014
Author(s): Christoph Baumgärtel, MD, MSc
authorization, bioequivalence, generics, product-specific bioequivalence guidance
DOI: 10.5639/gabij.2014.0301.009
12.089 views
Published on 09 February 2016
Author(s): Anne Tomalin, BA, BSc, Eric CK Siu, MSc, PhD, George Wyatt, BSc, MBA, Kevin West, BA, Sandra Anderson, BA, MBA
biosimilars, CADTH CDR, CADTH pCODR, Health Canada, INESSS, pCPA
DOI: 10.5639/gabij.2019.0803.014
11.919 views